Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$2.71 -0.9%	$2.68	$2.12 ▼ $5.80	$268.68M	2.02	1.51 million shs	322,308 shs
CLNN Clene	$2.69 +1.9%	$2.88	$2.28 ▼ $9.20	$24.03M	0.46	81,748 shs	19,529 shs
VSTM Verastem	$7.83 +2.8%	$6.57	$2.10 ▼ $9.10	$429.10M	0.85	1.08 million shs	624,748 shs
VTVT vTv Therapeutics	$16.67 -0.2%	$19.26	$12.12 ▼ $26.99	$53.25M	0.77	23,277 shs	1,763 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+7.06%	+20.26%	-3.53%	+0.37%	-11.94%
CLNN Clene	+0.76%	+5.60%	-12.87%	-40.27%	-61.17%
VSTM Verastem	-10.68%	0.00%	+8.87%	+40.15%	+89.30%
VTVT vTv Therapeutics	+4.05%	-13.68%	-27.92%	-9.17%	-32.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	1.2152 of 5 stars	3.5	1.0	2.2	0.0	0.0
CLNN Clene	2.527 of 5 stars	3.6	3.0	1.3	2.5	0.6
VSTM Verastem	3.1568 of 5 stars	4.5	0.0	3.9	2.5	0.6
VTVT vTv Therapeutics	2.319 of 5 stars	3.5	5.0	2.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$10.67	294.33% Upside
CLNN Clene	3.17	Buy	$40.00	1,386.99% Upside
VSTM Verastem	3.00	Buy	$13.63	74.12% Upside
VTVT vTv Therapeutics	3.00	Buy	$35.50	113.02% Upside

Current Analyst Ratings Breakdown

Latest VTVT, VSTM, CLNN, and AQST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/9/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
5/8/2025	CLNN Clene	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $33.00
5/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/23/2025	CLNN Clene	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
4/10/2025	VSTM Verastem	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/9/2025	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
4/9/2025	VTVT vTv Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00
4/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/8/2025	CLNN Clene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/2/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$54.23M	4.95	N/A	N/A	($1.59) per share	-1.70
CLNN Clene	$350K	69.04	N/A	N/A	$2.09 per share	1.29
VSTM Verastem	$10M	43.00	N/A	N/A	$2.27 per share	3.45
VTVT vTv Therapeutics	$17K	3,132.04	N/A	N/A	($9.27) per share	-1.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$7.87M	-$0.59	N/A	N/A	N/A	-59.75%	N/A	-33.96%	8/5/2025 (Estimated)
CLNN Clene	-$49.50M	-$4.04	N/A	N/A	N/A	-8,556.77%	-1,106.30%	-85.11%	8/6/2025 (Estimated)
VSTM Verastem	-$87.37M	-$3.20	N/A	N/A	N/A	N/A	-332.73%	-73.97%	8/14/2025 (Estimated)
VTVT vTv Therapeutics	-$20.25M	-$3.01	N/A	∞	N/A	N/A	-184.64%	-47.29%	8/14/2025 (Estimated)

Latest VTVT, VSTM, CLNN, and AQST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	VTVT vTv Therapeutics	-$0.73	-$0.77	-$0.04	-$0.77	N/A	N/A
5/13/2025	Q1 2025	VSTM Verastem	-$0.72	-$0.96	-$0.24	-$0.96	$0.10 million	N/A
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million
5/7/2025	Q1 2025	CLNN Clene	-$1.10	-$0.50	+$0.60	-$0.09	$0.07 million	$0.08 million
3/24/2025	Q4 2024	CLNN Clene	-$1.21	-$1.67	-$0.46	-$1.67	$0.13 million	$0.09 million
3/20/2025	Q4 2024	VSTM Verastem	-$0.76	-$1.33	-$0.57	-$1.33	$0.15 million	N/A
3/20/2025	Q4 2024	VTVT vTv Therapeutics	-$0.87	-$0.55	+$0.32	-$0.55	N/A	$0.02 million
3/5/2025	Q4 2024	AQST Aquestive Therapeutics	-$0.14	-$0.19	-$0.05	-$0.19	$13.11 million	$11.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
CLNN Clene	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A
VTVT vTv Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	6.37	5.91
CLNN Clene	N/A	0.83	0.82
VSTM Verastem	2.77	3.23	3.23
VTVT vTv Therapeutics	N/A	6.69	6.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
CLNN Clene	23.28%
VSTM Verastem	88.37%
VTVT vTv Therapeutics	17.51%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	8.35%
CLNN Clene	35.30%
VSTM Verastem	2.10%
VTVT vTv Therapeutics	4.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.33 million	84.02 million	Optionable
CLNN Clene	100	8.98 million	6.24 million	Optionable
VSTM Verastem	50	54.95 million	43.53 million	Optionable
VTVT vTv Therapeutics	9	3.20 million	3.15 million	Not Optionable

VTVT, VSTM, CLNN, and AQST Headlines

Recent News About These Companies

vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above Fifty Day Moving Average - Here's Why

May 26 at 5:14 AM | marketbeat.com

vTv resumes Phase III oral T1D drug study

May 21, 2025 | thepharmaletter.com

vTv Therapeutics Appoints Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer

May 19, 2025 | quiverquant.com

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025 | globenewswire.com

vTv Therapeutics (NASDAQ:VTVT) Stock Passes Above 50-Day Moving Average - Here's Why

May 18, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Precision BioSciences (DTIL)

May 17, 2025 | theglobeandmail.com

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025 | globenewswire.com

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025 | globenewswire.com

vTv Therapeutics (VTVT) to Release Quarterly Earnings on Thursday

May 3, 2025 | marketbeat.com

Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Expands By 42.2%

May 2, 2025 | marketbeat.com

vTv Therapeutics Appoints Barry Brown as Interim CFO

April 11, 2025 | tipranks.com

vTv Therapeutics initiated with a Buy at H.C. Wainwright

April 9, 2025 | markets.businessinsider.com

HC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation

April 9, 2025 | msn.com

vTv Therapeutics cleared to resume clinical trial of diabetes therapy

March 26, 2025 | ncbiotech.org

vTv Therapeutics reports Q4 EPS (55c) vs ($1.67) last year

March 21, 2025 | markets.businessinsider.com

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

March 20, 2025 | globenewswire.com

vTv Therapeutics Inc.: vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

March 18, 2025 | finanznachrichten.de

Alliance Global says clinical hold lift ‘de-risking’ event for vTv Therapeutics

March 18, 2025 | markets.businessinsider.com

vTv Therapeutics says FDA has lifted clinical hold on cadisegliatin program

March 17, 2025 | markets.businessinsider.com

vTv Therapeutics stock surges on FDA update

March 17, 2025 | au.investing.com

Vtv Therapeutics Shares Halted as FDA Clinical Hold on Diabetes Treatment Lifted

March 17, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT, VSTM, CLNN, and AQST Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$2.70 -0.03 (-0.92%)

As of 11:41 AM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Clene NASDAQ:CLNN

$2.69 +0.05 (+1.89%)

As of 11:37 AM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Verastem NASDAQ:VSTM

$7.82 +0.22 (+2.83%)

As of 11:41 AM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

vTv Therapeutics NASDAQ:VTVT

$16.66 -0.04 (-0.21%)

As of 11:36 AM Eastern

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time